HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Radiographic progression of asbestosis: preliminary report.

Abstract
In a collaborative study with the Pneumoconiosis Medical Panel, 232 asbestos workers were seen between 1967 and 1975. During this time, 50 of the 232 (21.5%) workers dies, 33 (13.8%) from respiratory disease probably related to asbestos exposure [10 (4.3%) pleural mesothelioma, three (1.3%) peritoneal mesothelioma, 10 (4.3%) asbestosis, 10 (4.3%) carcinoma of the lung]. Of the 182 survirors, 119 were recalled for other studies, and follow-up data were obtained as additional information at the same time, over a 1--7 year period. Paired radiographs were read, and 21 patients (17.6%) had worsened. As expected, the frequency of progression increased with a longer follow-up time, so that about one third of the subjects displayed progression after a minimum follow-up of 6 years. Ten of 73 patients (13.6%) had progressed in 3 years or less and may be defined as rapid progressors. No particular clinical feature distinguished clearly between progressors and nonprogressors, but there was a trend toward a greater frequency and higher titer of ANA among the progressors in this group. There was also a higher frequency of progression in those who were initially classified radiographically as 1/1 of 1/2 than in those with other initial radiographic appearances. This pilot study is now forming the basis for a larger, longer-term comprehensive survey.
AuthorsA Gregor, R W Parkes, R du Bois, M Turner-Warwick
JournalAnnals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 330 Pg. 147-56 ( 1979) ISSN: 0077-8923 [Print] United States
PMID316663 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antibodies, Antinuclear
Topics
  • Antibodies, Antinuclear (analysis)
  • Asbestosis (diagnostic imaging, immunology, mortality)
  • Epidemiologic Methods
  • Humans
  • London
  • Lung Neoplasms (mortality)
  • Mesothelioma (mortality)
  • Middle Aged
  • Occupational Diseases (mortality)
  • Peritoneal Neoplasms (mortality)
  • Pleural Neoplasms (mortality)
  • Radiography
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: